Antibody Protein ELISA Kit from MyBioSource header Telephone 1.858.633.0165          
1.855.MyBioSource
Fax 1.858.633.0166    Email sales@mybiosource.com 
tel/fax
menu1 Home Products Ordering Company Help menu7
bottom
   MyBioSource rightarrow Antibody rightarrow JAK2 (pY1007/Y1008) (Biotinylated)  rightarrow LOG IN  rightarrow MY ACCOUNT  rightarrow CART CONTENTS  rightarrow CHECKOUT 
horiz bar
MyBioSource Menu separator
separator
ELISA Kit ELISA Kit
CLIA Kit CLIA Kit
PCR Kit PCR Kit
Monoclonal Antibody Monoclonal Antibody
Polyclonal Antibody Polyclonal Antibody
Secondary Antibody Secondary Antibody
Antigen Antigen
Biochemical Biochemical
cDNA Clone cDNA Clone
siRNA siRNA
Peptide Peptide
Recombinant/Purified Protein Rec./Purified Protein

Custom ELISA Kit Custom ELISA Kit
Custom Protein Custom Protein
Custom Antibody Custom Antibody
Antibody Matched Pairs Antibody Matched Pairs
Antibody & Corresponding Blocking Peptide Pairs Antibody Peptide Pairs
Phospho-Specific Antibodies Phospho Antibodies
Products by Disease Products by Disease
Products by Pathway Products by Pathway
Products by Tissue Products by Tissue

arrow Advanced Search
arrow Submit Technical Q&A
arrow International Distributors
arrow Contact Us
separator
Our Best Sellers moreseparator
separator
 • transient receptor potential cation channel, subfamily V, me... ELISA Kit
 • Carboxylated Osteocalcin (cOC) ELISA Kit
 • deoxypyridinoline (DPD) ELISA Kit
 • Vitamin D Binding Protein (Gc-Globulin) Native Protein
 • Testosterone Antibody
 • Bone Morphogenetic Protein 6 (BMP6) ELISA Kit
 • CASR Blocking Peptide
 • Tissue type Plasminogen Activator (tPA) ELISA Kit
 • CSFV Structural Glycoprotein Antibody
 • ARNT2 Antibody
 • Anosmin-1 (KAL1), partial Recombinant Protein
 • Cystatin C (CST3) Antibody
 • Neurochondrin (NCDN) Antibody
 • SEPSECS Recombinant Protein
 downarrow more ...
separator
separator
DatasheetFull DatasheetPrinter Friendly DatasheetPrint This DatasheetAdd to Compare ListHave Questions? Ask UsRequest for a Quotation today

anti-JAK2 (pY1007/Y1008) (Biotinylated) antibody :: Rabbit JAK2 (pY1007/Y1008) (Biotinylated) Antibody

Scan QR to view Datasheet Catalog #    MBS462108
Testing Data
Unit / Price
0.1 mg  /  $285 +1 FREE 8GB USB
 
 Go to:   rightarrow  Product Names   rightarrow Product Info   rightarrow Accession #s   rightarrow Product Desc   rightarrow Diseases/Tissues/Pathways   rightarrow Applications   rightarrow References 
 Product Name   

JAK2 (pY1007/Y1008) (Biotinylated) (JAK2 (pY1007/Y1008) (Biotinylated)), Antibody

★Popular Item★
 Also Known As   

Rabbit anti Phospho- JAK2 (pTyr 1007/1008)Biotinylated

 Product Synonym Names    Rabbit anti-Phospho-JAK2 (pY1007/1008); Biotinylated; Biotin-conjugated Rabbit anti phosphospecifici-Janus Kinase 2
 Product Gene Name   

anti-JAK2 (pY1007/Y1008) (Biotinylated) antibody

[Similar Products]
 Research Use Only    For Research Use Only. Not for use in diagnostic procedures.
Table BarTOPTable Bar
 Chromosome Location    Chromosome: 9; NC_000009.11 (4985245..5128183). Location: 9p24
 OMIM    147796
 3D Structure    ModBase 3D Structure for O60674
Section Bar
 Host    Rabbit
 Species Reactivity    Human, Rat, Mouse
Section Bar
 Specificity    This biotinylated antibody recognizes JAK2 with dual phosphorylated sites of Tyr1007/1008. It does not crossreact with non-phosphospecific peptide.
 Purity/Purification    The Rabbit IgG is purified by site-modified Epitope Affinity Purification.
 Form/Format    This affinity purified antibody is supplied in sterile Tris-buffered saline (pH7.2) containing antibody stabilizer
 Concentration    Size: 100 ug/200 ul (lot specific)
Section Bar
 Antigen Preparation    A synthetic peptide surrounding to the epitope -EYYK- with dual phosphorylation sites at Tyr1008 and Tyr1009 of JAK2 from human, mouse and rat origins.
 Positive Control    GH stimulated mouse liver
 Cellular Location    Cytoplasmic
Section Bar
 Preparation and Storage    The antibodies are stable for 12 months from date of receipt when stored at -20 degree C to -70 degree C. The antibodies can be stored at 2 degree C-8 degree C for three month without detectable loss of activity. Avoid repeated freezing-thawing cycles.
 Other Notes    Small volumes of anti-JAK2 (pY1007/Y1008) (Biotinylated) antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Table BarTOPTable Bar
 

Product Description specifically for anti-JAK2 (pY1007/Y1008) (Biotinylated) antibody

   The Janus tyrosine kinase family is consists of four members, JAK1, JAK2, JAK3 and Tyk2. Upon the cytokine ligand binding to its the receptors, the dimerization of the receptors occurs followed by phosphorylation of the receptors. The phosphorylation of receptors recruites the tyrosine kinase physically associated to the dimerized receptors, and the phosphorylate the kinase, thus activates the signal transducer and activator of thranscription (STAT1, 3, 5) and the other signal proteins
 Applications Tested/Suitable for anti-JAK2 (pY1007/Y1008) (Biotinylated) antibody   

ELISA, Western Blot, Immunohistochemistry

 Application Notes for anti-JAK2 (pY1007/Y1008) (Biotinylated) antibody    Western Blot: 0.1-1 ug/ml
ELISA: 0.01-0.1 ug/ml
Immunoprecipitation: 2-5 ug/ml
Immunohistochemistry: 1-5 ug/ml
Section Bar
 Testing Data of anti-JAK2 (pY1007/Y1008) (Biotinylated) antibody    anti-JAK2 (pY1007/Y1008) (Biotinylated) antibody Testing Data image
Table BarTOPTable Bar
NCBI/Uniprot data below describe general gene information for JAK2 (pY1007/Y1008) (Biotinylated). It may not necessarily be applicable to this product.
 NCBI GI #    4826776
 NCBI GeneID    3717
 NCBI Accession #    NP_004963.1 [Other Products]
 NCBI GenBank Nucleotide #    NM_004972.2 [Other Products]
Section Bar
 UniProt Primary Accession #    O60674 [Other Products]
 UniProt Secondary Accession #    O14636; O75297 [Other Products]
 UniProt Related Accession #    O60674; Q506Q0; Q52R86; Q8IXP2 [Other Products]
 Molecular Weight    120 kDa (130kDa)
Table BarTOPTable Bar
 NCBI Official Full Name    tyrosine-protein kinase JAK2
 NCBI Official Synonym Full Names    Janus kinase 2
 NCBI Official Symbol    JAK2 [Similar Products]
 NCBI Official Synonym Symbols   
JTK10
[Similar Products]
 NCBI Protein Information    tyrosine-protein kinase JAK2; JAK-2; OTTHUMP00000021024; Janus kinase 2 (a protein tyrosine kinase)
 UniProt Protein Name    Tyrosine-protein kinase JAK2
 UniProt Synonym Protein Names   
Janus kinase 2
 UniProt Gene Name    JAK2 [Similar Products]
 UniProt Entry Name    JAK2_HUMAN
Section Bar
 NCBI Summary for JAK2 (pY1007/Y1008) (Biotinylated)    This gene product is a protein tyrosine kinase involved in a specific subset of cytokine receptor signaling pathways. It has been found to be constituitively associated with the prolactin receptor and is required for responses to gamma interferon. Mice that do not express an active protein for this gene exhibit embryonic lethality associated with the absence of definitive erythropoiesis. [provided by RefSeq]
Section Bar
 UniProt Comments for JAK2 (pY1007/Y1008) (Biotinylated)    Function: Non-receptor tyrosine kinase involved in various processes such as cell cycle progression, apoptosis, mitotic recombination, genetic instability and histone modifications. In the cytoplasm, plays a pivotal role in signal transduction via its association with cytokine receptors, which constitutes an initiating step in signaling for many members of the cytokine receptor superfamily including the receptors for growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), granulocyte-macrophage colony-stimulating factor (CSF2), thrombopoietin (THPO) and multiple interleukins. Following stimulation with erythropoietin (EPO) during erythropoiesis, it is autophosphorylated and activated, leading to its association with erythropoietin receptor (EPOR) and tyrosine phosphorylation of residues in the EPOR cytoplasmic domain. Also involved in promoting the localization of EPOR to the plasma membrane. Also acts downstream of some G-protein coupled receptors. Plays a role in the control of body weight

By similarity. Mediates angiotensin-2-induced ARHGEF1 phosphorylation. In the nucleus, plays a key role in chromatin by specifically mediating phosphorylation of 'Tyr-41' of histone H3 (H3Y41ph), a specific tag that promotes exclusion of CBX5 (HP1 alpha) from chromatin. Ref.7 Ref.14 Ref.16

Catalytic activity: ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.

Enzyme regulation: Regulated by autophosphorylation, can both activate or decrease activity

By similarity. Heme regulates its activity by enhancing the phosphorylation on Tyr-1007 and Tyr-1008. Ref.15

Subunit structure: Interacts with EPOR, SIRPA and SH2B1

By similarity. Interacts with IL23R, SKB1 and STAM2. Ref.5 Ref.6 Ref.7

Subcellular location: Endomembrane system; Peripheral membrane protein

By similarity. Nucleus Ref.14.

Tissue specificity: Expressed in blood, bone marrow and lymph node. Ref.12

Domain: Possesses 2 protein kinase domains. The second one probably contains the catalytic domain, while the presence of slight differences suggest a different role for protein kinase 1

Post-translational modification: Autophosphorylated, leading to regulate its activity. Leptin promotes phosphorylation on tyrosine residues, including phosphorylation on Tyr-813. Autophosphorylation on Tyr-119 in response to EPO down-regulates its kinase activity. Autophosphorylation on Tyr-868, Tyr-966 and Tyr-972 in response to growth hormone (GH) are required for maximal kinase activity

By similarity. Ref.13 Ref.17

Involvement in disease: Note=Chromosomal aberrations involving JAK2 are found in both chronic and acute forms of eosinophilic, lymphoblastic and myeloid leukemia. Translocation t(8;9)(p22;p24) with PCM1 links the protein kinase domain of JAK2 to the major portion of PCM1. Translocation t(9;12)(p24;p13) with ETV6.Defects in JAK2 are a cause of susceptibility to Budd-Chiari syndrome (BCS) [

MIM:600880]. It is a syndrome caused by obstruction of hepatic venous outflow involving either the hepatic veins or the terminal segment of the inferior vena cava. Obstructions are generally caused by thrombosis and lead to hepatic congestion and ischemic necrosis. Clinical manifestations observed in the majority of patients include hepatomegaly, right upper quadrant pain and abdominal ascites. Budd-Chiari syndrome is associated with a combination of disease states including primary myeloproliferative syndromes and thrombophilia due to factor V Leiden, protein C deficiency and antithrombin III deficiency. Budd-Chiari syndrome is a rare but typical complication in patients with polycythemia vera.Defects in JAK2 are a cause of polycythemia vera (PV) [

MIM:263300]. A myeloproliferative disorder characterized by abnormal proliferation of all hematopoietic bone marrow elements, erythroid hyperplasia, an absolute increase in total blood volume, but also by myeloid leukocytosis, thrombocytosis and splenomegaly. Ref.18 Ref.21 Ref.22 Ref.25Defects in JAK2 gene may be a cause of essential thrombocythemia (ET) [

MIM:187950]. ET is characterized by elevated platelet levels due to sustained proliferation of megakaryocytes, and frequently lead to thrombotic and haemorrhagic complications. Ref.3 Ref.20Defects in JAK2 are a cause of myelofibrosis (MYELOF) [

MIM:254450]. Myelofibrosis is a disorder characterized by replacement of the bone marrow by fibrous tissue, occurring in association with a myeloproliferative disorder. Clinical manifestations may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension.Defects in JAK2 are a cause of acute myelogenous leukemia (AML) [

MIM:601626]. AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development. Ref.24

Sequence similarities: Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily.Contains 1 FERM domain.Contains 1 protein kinase domain.Contains 1 SH2 domain.
Table BarTOPTable Bar
 

Product References and Citations for anti-JAK2 (pY1007/Y1008) (Biotinylated) antibody

   Yogev,O., et al. SHP-2 regulates SOCS-1-mediated Janus kinase-2 ubiquitination/degradation downstream of the prolactin receptor. J. Biol. Chem. 278 (52), 52021-52031 (2003)
Section Bar
 Research Articles on JAK2 (pY1007/Y1008) (Biotinylated)    1. Acquired mutation of the tyrosine kinase JAK2V617F in Egyptian patients with myeloid disorders
Table BarTOPTable Bar
 Precautions    All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
 Disclaimer    While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Table BarTOPTable Bar
Products associated with anti-JAK2 (pY1007/Y1008) (Biotinylated) antibodyPathways associated with anti-JAK2 (pY1007/Y1008) (Biotinylated) antibody
 Reference Product  PubMed Publications
 STAT3 antibody  >1068 publications with JAK2 (pY1007/Y1008) (Biotinylated) and STAT3
 STAT1 antibody  >562 publications with JAK2 (pY1007/Y1008) (Biotinylated) and STAT1
 BCR antibody  >331 publications with JAK2 (pY1007/Y1008) (Biotinylated) and BCR
 JAK3 antibody  >271 publications with JAK2 (pY1007/Y1008) (Biotinylated) and JAK3
 MPL antibody  >235 publications with JAK2 (pY1007/Y1008) (Biotinylated) and MPL
 EPOR antibody  >164 publications with JAK2 (pY1007/Y1008) (Biotinylated) and EPOR
 GHR antibody  >151 publications with JAK2 (pY1007/Y1008) (Biotinylated) and GHR
 CSF3R antibody  >145 publications with JAK2 (pY1007/Y1008) (Biotinylated) and CSF3R
 SOCS3 antibody  >144 publications with JAK2 (pY1007/Y1008) (Biotinylated) and SOCS3
 SOCS1 antibody  >142 publications with JAK2 (pY1007/Y1008) (Biotinylated) and SOCS1
 Products by Pathway  Pathway Diagram
 Adipocytokine Signaling Pathway antibodies  Adipocytokine Signaling Pathway Diagram
 Adipocytokine Signaling Pathway antibodies  Adipocytokine Signaling Pathway Diagram
 CXCR4-mediated Signaling Events Pathway antibodies  CXCR4-mediated Signaling Events Pathway Diagram
 Chemokine Signaling Pathway antibodies  Chemokine Signaling Pathway Diagram
 Chemokine Signaling Pathway antibodies  Chemokine Signaling Pathway Diagram
 Cholinergic Synapse Pathway antibodies  Cholinergic Synapse Pathway Diagram
 Cytokine Signaling In Immune System Pathway antibodies  Cytokine Signaling In Immune System Pathway Diagram
 Delta-Notch Signaling Pathway antibodies  Delta-Notch Signaling Pathway Diagram
 EGFR1 Signaling Pathway antibodies  EGFR1 Signaling Pathway Diagram
 EPO Receptor Signaling Pathway antibodies  EPO Receptor Signaling Pathway Diagram
Diseases associated with anti-JAK2 (pY1007/Y1008) (Biotinylated) antibodyOrgans/Tissues associated with anti-JAK2 (pY1007/Y1008) (Biotinylated) antibody
 Disease Name  Pubmed Publications
 Hematologic Diseases Antibodies  >1253 publications with JAK2 (pY1007/Y1008) (Biotinylated) and Hematologic Diseases
 Myeloproliferative Disorders Antibodies  >1174 publications with JAK2 (pY1007/Y1008) (Biotinylated) and Myeloproliferative Disorders
 Neoplasms Antibodies  >1113 publications with JAK2 (pY1007/Y1008) (Biotinylated) and Neoplasms
 Leukemia Antibodies  >855 publications with JAK2 (pY1007/Y1008) (Biotinylated) and Leukemia
 Polycythemia Antibodies  >656 publications with JAK2 (pY1007/Y1008) (Biotinylated) and Polycythemia
 Polycythemia Vera Antibodies  >630 publications with JAK2 (pY1007/Y1008) (Biotinylated) and Polycythemia Vera
 Thrombocythemia, Essential Antibodies  >478 publications with JAK2 (pY1007/Y1008) (Biotinylated) and Thrombocythemia, Essential
 Thrombocytosis Antibodies  >375 publications with JAK2 (pY1007/Y1008) (Biotinylated) and Thrombocytosis
 Primary Myelofibrosis Antibodies  >354 publications with JAK2 (pY1007/Y1008) (Biotinylated) and Primary Myelofibrosis
 Cardiovascular Diseases Antibodies  >329 publications with JAK2 (pY1007/Y1008) (Biotinylated) and Cardiovascular Diseases
 Organ/Tissue Name  Pubmed Publications
 Blood Antibodies  >1129 publications with JAK2 (pY1007/Y1008) (Biotinylated) and Blood
 Bone Antibodies  >462 publications with JAK2 (pY1007/Y1008) (Biotinylated) and Bone
 Bone Marrow Antibodies  >429 publications with JAK2 (pY1007/Y1008) (Biotinylated) and Bone Marrow
 Vascular Antibodies  >305 publications with JAK2 (pY1007/Y1008) (Biotinylated) and Vascular
 Muscle Antibodies  >237 publications with JAK2 (pY1007/Y1008) (Biotinylated) and Muscle
 Liver Antibodies  >232 publications with JAK2 (pY1007/Y1008) (Biotinylated) and Liver
 Brain Antibodies  >164 publications with JAK2 (pY1007/Y1008) (Biotinylated) and Brain
 Kidney Antibodies  >128 publications with JAK2 (pY1007/Y1008) (Biotinylated) and Kidney
 Spleen Antibodies  >97 publications with JAK2 (pY1007/Y1008) (Biotinylated) and Spleen
 Lung Antibodies  >81 publications with JAK2 (pY1007/Y1008) (Biotinylated) and Lung
Table BarTOPTable Bar
horiz bar
 SSL   Follow us on Facebook Follow us onTwitter Follow us on Google Plus Connect us on LinkedIn Subscribe to our RSS Feed for latest products and special promotions